Capstone Investment Advisors
OVID icon

Capstone Investment Advisors’s Ovid Therapeutics OVID Stock Holding History

Capstone Investment Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,291
Closed -$55K – 2029
2021
Q3 		$55K Buy
+16,291
New +$59.4K ﹤0.01% 1843

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capstone Investment Advisors's OVID Position: Q4 2021 in Review

Capstone Investment Advisors sold out of Ovid Therapeutics (OVID) in Q4 2021, closing a stake of 16,291 shares — an estimated $55K sold.

Capstone Investment Advisors first reported a position in OVID in Q3 2021 and held it in 1 quarter. The position peaked at $55K in Q3 2021. 67 funds tracked by Wall St. Rank hold OVID as of Q4 2021.

  • Capstone Investment Advisors reported no remaining Ovid Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 16,291 Ovid Therapeutics shares in Q4 2021, an estimated $55K.
  • Capstone Investment Advisors first reported a position in Ovid Therapeutics in Q3 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Ovid Therapeutics position peaked at $55K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.